Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2014-09-03 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about initiating a Phase III study but does not contain detailed financial statements or comprehensive financial analysis. The document length is short (2287 characters), and it primarily serves as a regulatory announcement rather than a full report. According to the rules, Form 6-K filings are typically classified under Regulatory Filings (RNS) as they are miscellaneous regulatory announcements that do not fit into other specific categories like Annual Report or Interim Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2014-09-03 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release update on a clinical study expansion but does not contain detailed financial statements or comprehensive financial analysis. The document length is short (2348 characters), and it primarily serves as an announcement rather than a full report. According to the rules, Form 6-K filings that provide updates or press releases without substantive financial data or detailed reports are classified as Regulatory Filings (RNS).
2014-08-27 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about an acquisition option for a Phase II pancreatic cancer drug. The document is short (2280 characters) and primarily serves as an announcement of a press release rather than a detailed financial report or comprehensive filing. It does not contain financial statements or detailed analysis. According to the rules, such filings that are announcements or brief reports without substantive financial data fall under Regulatory Filings (RNS).
2014-08-13 English
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release reporting second quarter 2014 results and condensed interim unaudited financial information for the six months ended June 30, 2014. Form 6-K is used by foreign private issuers to report material information between annual reports. The content includes interim financial data but is not a full annual report. Given the presence of interim unaudited financial information and quarterly results, this aligns with an Interim / Quarterly Report. The document length is short (2013 characters), but it contains substantive financial data, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2014-07-23 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release announcing a conference call for the second quarter 2014 financial results. The document itself does not contain financial statements or detailed financial data but rather announces an event related to financial results. The length is 2295 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the actual financial report or transcript.
2014-07-16 English
Regulatory Filings 2014
Regulatory Filings
2014-07-14 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.